Lorenzo A Calo
Overview
Explore the profile of Lorenzo A Calo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
238
Citations
1633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Francini-Pesenti F, Favaretto S, DAngelo M, Cacciapuoti M, Calo L
Nutrients
. 2025 Jan;
16(24.
PMID: 39770945
Despite advances in pharmacological therapies, migraine patients are often drug resistant. Further therapeutic options in this field are, therefore, desirable. Recent studies have highlighted the efficacy of ketogenic diet (KD)...
2.
Cacciapuoti M, Basso A, Stefanelli L, Nalesso F, Calo L
Life (Basel)
. 2024 Nov;
14(11).
PMID: 39598273
Peritoneal catheter dysfunction is one of the most frequent complications of peritoneal dialysis. The malposition of a peritoneal catheter may cause one- or two-way obstruction with fluid outflow or inflow...
3.
Cacciapuoti M, Stefanelli L, Calo L
Clin Nephrol
. 2024 Oct;
103(1):69-70.
PMID: 39474823
No abstract available.
4.
Giordani A, Menghi C, Proietti R, Stefanelli L, Cacciapuoti M, Calo L
J Hypertens
. 2024 Oct;
43(2):191-200.
PMID: 39445629
Bartter's and Gitelman's syndromes (BS/GS) are genetically determined kidney tubulopathies leading to electrolyte and neurohormonal abnormalities. Although considered benign entities, major adverse cardiovascular events may complicate both syndromes, in form...
5.
Cacciapuoti M, Stefanelli L, Nalesso F, Calo L
J Cardiovasc Med (Hagerstown)
. 2024 Sep;
25(11):808-809.
PMID: 39347730
No abstract available.
6.
Basso A, Cacciapuoti M, Stefanelli L, Nalesso F, Calo L
Life (Basel)
. 2024 Sep;
14(9).
PMID: 39337956
Oxidative stress (OxSt) and inflammation are common in end-stage renal disease and dialysis patients; they are known risk factors for cardiovascular disease and mortality. In peritoneal dialysis (PD), OxSt and...
7.
Martino F, Campo D, Stefanelli L, Zattarin A, Piccolo D, Cacciapuoti M, et al.
Nutrients
. 2024 Sep;
16(17).
PMID: 39275352
Background/objectives: Comprehensive conservative management (CCM) is a viable treatment option for elderly patients with end-stage kidney disease (ESKD). However, it involves a significant change in dietary habits, such as adopting...
8.
Nalesso F, Bertacco A, Bettin E, Cacciapuoti M, Bogo M, Cattarin L, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274427
The possibility of keeping liver grafts viable and functioning until transplantation has been explored since the 1950s. However, the current modalities of Normothermic Machine Perfusion (NMP) have shown several limitations,...
9.
Martino F, di Vico V, Basso A, Gobbi L, Stefanelli L, Cacciapuoti M, et al.
Life (Basel)
. 2024 Aug;
14(8).
PMID: 39202706
Managing mineral bone disease (MBD) could reduce cardiovascular risk and improve the survival of dialysis patients. Our study focuses on the impact of calcium bath exposure in dialysis patients by...
10.
Cacciapuoti M, Bertoldi G, Caputo I, Driussi G, Carraro G, Calo L
J Nephrol
. 2024 Jun;
37(5):1201-1207.
PMID: 38878155
Fabry disease is a rare X-linked disease characterized by deficient expression and activity of alpha-galactosidase A with consequent lysosomal accumulation of glycosphingolipids, particularly globotriaosylceramide in various organs. Currently, enzyme replacement...